Kintor net loss narrows 9% to RMB 75.8 million in 1H FY26; revenue rises to RMB 52 million

• Kintor posted revenue of RMB 52 million, up 766.7% year over year, driven by global sales of its KOSHINÉ cosmetics brand.
• Net loss narrowed 9% to RMB 75.8 million, on lower R&D costs of RMB 27.4 million, down 43.7%.
• Selling and marketing expenses jumped to RMB 57.5 million, up 595.2%, mainly on higher marketing and promotion spending.
• Cash and cash equivalents stood at RMB 31.3 million, with unutilised bank facilities of RMB 70.1 million.
• KX-826 phase III pivotal trial for male AGA in China hit its primary endpoint; NDA filing expected in 2026, approval targeted in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12291232), on August 19, 2026, and is solely responsible for the information contained therein.